Dear Friends and Investors,

Please join us for a special Private Investor Dinner on Wednesday, November 6 at 5:30 PM EST featuring Orion Biotechnology. Orion Biotechnology is developing next generation GPCR targeted therapeutics for metabolic disorders.

This meeting is only for accredited investors, investment advisors, and potential partners of the company.

OPPORTUNITY:

Current obesity drugs (e.g. Ozempic) have proven the market but induce negative side effects and have important clinical limitations. Leveraging a new approach and proprietary drug discovery platform to target G Protein-Coupled Receptors (GPCRs), Orion Biotechnology Canada Ltd. is advancing multiple obesity drug candidates with novel mechanisms of action that have the potential to overcome these limitations and become next-generation obesity drugs.

KEY INVESTMENT CONSIDERATIONS

• Potential Blockbuster Lead Obesity Program - Orion’s GPR75 obesity program has a novel mechanism of action which could overcome the limitations of currently available treatments and become the next-generation obesity drug.

• Proven Leadership Team - Orion is backed by a world class management team and board with proven track record, more than $3B in prior successful exits, and highly recognized scientific leadership including a Nobel prize winner that has three major biotech exits based on his research.

• First Mover Advantage – Orion ‘s GPR75 obesity program is one of the most advanced in the industry targeted to be in the clinic in 2025.

• High Potential Return - other companies with similar programs have demonstrated that Orion’s GPR75 obesity program has a multi-billion-dollar valuation potential.

• Proprietary GPCR Technology – Orion has developed a novel approach and proprietary drug discovery platform (PROcisionXTM) designed to effectively target valuable GPCRs with industry leading efficiency.

• Strong Risk Mitigation - Orion’s platform technology provides the company with multiple “shots on goal” and its drug candidates can be monetized at early stages of development without being fully commercialized.

• Short-Term Return Potential - Orion has validated its technology and is poised to reach critical value inflection milestones over the next 12-24 months.

DEAL HIGHLIGHTS:

• Funding History: Orion has raised over $39.6M of funding to date, which includes the award of over $5.5M in prestigious grants.

• Fundraise: $5M Series A Extension - the company recently closed and oversubscribed a $15M Series A round of financing and currently has an open $5M extension of the Series A round.

• Fundraise/Terms: priced round, $1.70/share, participating preferred shares offered with a 1x Preference

• Pre-money Valuation: $50M

• Lead Investor: Keiretsu Capital

Location

The Tower Club

8000 Towers Crescent Dr

Suite 1700

Vienna, VA 22182

If you would like more information such as the Company's executive summary and/or investment deck, please email Skylar Rallison at srallison@opus8.com.

We look forward to seeing you on November 6!

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Thanks much and all the best,

The Opus8 Team